Pacific Biosciences of California

Pacific Biosciences of California, which operates as PacBio, develops long-read sequencing instruments, consumables, and analysis software for genomics. Its instrument portfolio includes the Revio and Vega long-read systems, alongside short-read Onso sequencing, and it publishes a technology roadmap covering HiFi long-read sequencing, Nanobind DNA extraction, Kinnex, and PureTarget enrichment. Consumables span sample preparation, library preparation and barcoding, application kits, and sequencing reagents, while bioinformatics is supported by SMRT Link, Onso software, computational tools, and compatible third-party software.

The company positions its platforms around sequencing methods including whole genome sequencing (human, plant and animal, microbiology and infectious disease), variant detection, targeted sequencing, bulk and single-cell RNA sequencing, epigenetics, microbiome and metagenomics, and multiomics. Focus areas listed by the company include human genomics, genetic testing, clinical research, rare disease, repeat expansions, population genetics, neurogenomics, immunogenomics, microbial genomics and public health surveillance, plant and animal genomics, agrigenomics, biodiversity, environmental health, cancer genomics and transcriptomics, and biopharma applications such as gene therapy, gene editing, and biologics R&D.

Recent product activity includes a Kinnex full-length RNA kit for isoform sequencing, which the company states produces 15 million reads per SMRT Cell on Sequel II and 40 million reads per SMRT Cell on Revio, a roughly 15-fold throughput increase on Revio; and an expanded PureTarget roadmap adding an updated repeat expansion panel, a new carrier screening panel, a 96-plex automation kit, and a carrier screening software pipeline aimed at higher-throughput clinical and diagnostic research workflows.

Business model

PacBio sells sequencing instruments together with recurring consumables and kits (sample prep, library prep and barcoding, application kits, sequencing reagents) and provides accompanying analysis software, documentation, technical support, and training. Purchasing routes include direct sales teams for the Americas, EMEA, and APAC, global distributors, and a PacBio Capital financing option, with pricing available on request.

Revenue is generated from sales of sequencing systems and associated consumables and application kits, supported by service and support offerings; the company also reports quarterly financial results publicly.

Traction

The company maintains a resource library of more than 10,000 articles, reports, papers, and videos, publishes customer success stories such as Uppsala University's Genome of Sweden national genomics project using Revio with SPRQ-Nx, and reports quarterly financial results, including second quarter 2026 results announced in August 2026.

Latest developments

In August 2026 PacBio announced the appointment of Mark Van Oene as President and Chief Executive Officer, reported second quarter 2026 financial results, and announced faster runs, up to 50% more HiFi data, and new compliance controls for the Vega system. Related content in the same period covered SPRQ-Nx performance on Vega for benchtop HiFi sequencing and telomere-to-telomere genome assembly across the tree of life.